Skip to main content

Durability of Response Among Psoriatic Arthritis (PsA) Patients Using Biological/Targeted Synthetic Disease-Modifying Antirheumatic Drugs (b/tsDMARDs) in the CorEvitas PsA/Spondyloarthritis Registry

  • Sponsored by CorEvitas, LLC. And UCB Pharma
Jan 31, 2024 2:10 pm

ADD THE FIRST COMMENT

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.